Controversial Issues in Current Treatment of Chronic HBV Infection

Abstract

The management of patients with progressive chronic hepatitis B infection (CHB) has undergone dramatic changes in the last decade, with the introduction of newer and more potent agents. Detailed international guidelines exist that provide advice for the optimal care of CHB patients. Despite that, several topics such as optimal treatment indication, choice of treatment type, and the discontinuation of nucleos(t)ide analogue therapy remain controversial, as relevant recommendations and expert opinions often vary widely. This review addresses these topics in more detail aiming to provide some clarifications taking into account the most recent data from the available literature.